Arkuda Therapeutics gets $64m booster to advance neurodegenerative treatment
Arkuda Therapeutics, a US-based biotechnology company, has raised $64 million in Series B financing. The new funding will help Arkuda Therapeutics boost the production of ... Read More
Novartis acquires Vedere Bio to advance optogenetic gene therapy for vision restoration
In a significant acquisition that could reshape the landscape of gene therapy for vision restoration, Swiss pharmaceutical giant Novartis has acquired Vedere Bio, a US-based ... Read More